Hoth: No plans for public or private offering

 The Company affirms that it has no plans for a public or private offering at this time.

Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.

Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants.

https://www.prnewswire.com/news-releases/hoth-therapeutics-responds-to-market-rumors-and-shareholder-inquiries-302346186.html